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Introduction
Nasal polyposis (NP), one of the clinical phenotypes of 
chronic rhinosinusitis, is recognized as being a major health 
problem, frequently encountered in otorhinolaryngologi-
cal practice. NP is a chronic inflammatory condition of the 
upper respiratory tract with incompletely understood etiol-
ogy [1-5]. NP is characterized by formation of nasal polyps, 
benign formations, arising from the mucosa of the parana-
sal sinuses or nasal cavity, and often manifested by a high 
tendency of recurrent growth even after surgical excision 
[1, 5-7]. NP is responsible for affecting the patient’s quality 
of life (QoL) more than other chronic diseases, resulting in 
enormous socioeconomic consequences [1, 5, 8]. Olfactory 
dysfunction developed in NP can be debilitating with sub-
stantial impact on QoL [9]. Patients with NP express vary-
ing sleep disturbances in high proportion leading to an im-
pairment of cognitive function and depression [10]. NP is 
still generating significant healthcare costs: the direct and 
indirect cost of lost working days [8, 11-13].
NP is attracting considerable interest due to its misun-
derstood pathogenesis. NP is widely considered a multi-
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Abstract
Background: Nasal polyposis (NP) is a multifactorial pathology with negative impact on quality of life. The pathogenesis of NP has not been fully 
elucidated. This limits the pathogenic treatment. Recent studies suggest that nitric oxide (NO) and its metabolites are involved in pathophysiological 
events of NP. Purpose of the study: to evaluate the tissue NO and nitrite/nitrate (NO2
-/NO3
-) levels in patients with and without NP and to establish the 
relationship between NO levels and some clinical features.
Material and methods: 86 recruited patients were divided into a case group (N1=43), patients with NP and a control group (N2=43), patients with septal 
deviations and turbinate hypertrophies. Visual Analog Scale (VAS) was used to evaluate the severity of nasal obstruction and olfactory disturbances. NO 
and NO2
-+NO3
- concentrations in tissue specimens were measured by spectrometric method.
Results: Case group had significantly lower NO (U=173.5, p<0.001) and NO2
-+NO3
- levels (U=123.5, p<0.001). A negative correlation was found between 
VAS for nasal obstruction and NO levels (rs = -0.379, p<0.05), between VAS for olfactory disturbances and NO levels (rs = -0.531, p<0.001), and between 
endoscopic score and NO levels (rs = -0.758, p<0.05).
Conclusions: Our results corroborate the previous findings. This underlines that NO levels depend on the patency of sinus ostium and the state of 
osteomeatal complex. Further studies, which take into account the role of NO in different rhinosinusitis endotypes, are needed to be performed in order 
to improve the NP management.
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factorial pathology, inflammation playing one of the most 
important roles. Nevertheless, the causes that determine 
the persistence of chronic inflammation with nasal polyps 
formation, have not yet been fully established [1-3, 13-15]. 
There is a considerable amount of literature on the role of 
multiple factors (infectious and noninfectious inflamma-
tion, anatomic and genetic abnormalities, oxidative stress, 
aspirin intolerance/sensitivity, environmental factors) in-
volved in the pathogenesis of NP [1, 16-18]. Therefore, 
pathogenic treatment of NP remains a challenging issue. 
Approximately 20% of patients are facing an uncontrolled 
pathology despite adequate medical therapy and modern 
sinus surgery [7, 19].
In recent years there has been considerable growing in-
terest regarding the involvement of nitric oxide (NO) in the 
pathogenesis of NP [20-24]. Current understanding sup-
ports that NO and its counterpart reactive nitrogen species 
may participate in pathophysiological events in a variety of 
inflammatory diseases, including NP [20, 25]. The primary 
source of NO in the respiratory tract seems to be the para-
nasal sinuses. NO is involved in upper airway homeostasis 
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and immunity by modulating blood flow, regulating muco-
ciliary clearance and acting as an antiviral and antimicrobial 
agent. Notwithstanding the fact that NO protects, it may ex-
presses toxic effect under certain condition [20]. The exact 
role of NO in respiratory homeostasis and pathophysiology 
is still unclear. The purpose of this study was consequently 
to further current knowledge of involvement of NO in NP 
pathogenesis and to determine relationship between NO 
level and some clinical features.
Material and methods
This study involved eighty-six patients from the 
Otolaryngology Department of Timofei Mosneaga Repub-
lican Clinical Hospital (Chisinau, the Republic of Moldova). 
Prior to subject recruitment, the study protocol was reviewed 
and approved by the Research Ethics Committee of Nicolae 
Testemitanu State University of Medicine and Pharmacy 
(SUMPh), the Republic of Moldova (Report No 30 of 
29.03.2016). Written informed consent was obtained from 
all patients at the beginning of the study. From 2016 to 2019, 
eighty-six patients with NP, septal deviations and middle 
concha hypertrophies were recruited for the study. Patients 
were divided into two groups: group 1 – Case (N1= 43) 
consisted of patients with NP, and group 2 – Control 
(N2= 43) consisted of patients with septal deviations and 
middle concha hypertrophies. Patients with septal devia-
tions and middle concha hypertrophies have nasal obstruc-
tion, comparable according to VAS to that of NP. The diag-
nosis was based on history, anterior rhinoscopy, endoscopic 
examination and paranasal sinus computed tomography 
(CT), CT was done by all the patients with NPs and some 
cases of middle concha hypertrophies. Endoscopy findings 
were scored according to the Lund and Kennedy scoring 
system [26]. The parameters, such as presence or absence 
and extent of nasal polyps, edema, and discharge were grad-
ed. For nasal polyps, 0 was given for the absence of polyps, 
1 for polyps present within the middle meatus, and 2 for 
polyps beyond the middle meatus.
Routine blood sampling, blood biochemistry and uri-
nalysis were performed to verify the presence of any illness 
that would be the exclusion criteria. The exclusion criteria 
included the following: age <18 years; pregnancy; severe 
chronic diseases (liver, kidney, cardiovascular, respiratory, 
malignancy, diabetes mellitus); chronic alcoholism; recent 
use (last four weeks) of topical or systemic glucocorticoids; 
refusal to participate in the study. 
The Visual Analog Scale (VAS) was used to evaluate the 
severity of the nasal obstruction and severity of olfactory 
disturbances by scoring them on a continuous 10-cm hori-
zontal line on which 0 cm represented no complaints and 
10 cm – serious complaints, associated with nasal obstruc-
tion and olfactory disturbances, respectively. The SinoNasal 
Outcome Test-22 (SNOT-22) test was used in order to eval-
uate the severity of nasal symptoms and their influence on 
the QoL.
Tissue specimens were collected from all patients in-
volved in the study. Polyp specimens were taken from all pa-
tients who underwent endoscopic surgery for NP. Control 
specimens (nasal mucosae) were obtained from patients who 
underwent an operation for septoplasty or concha hypertro-
phy. The freshly obtained tissue samples were immediately 
transferred to laboratory and stored at -70º C until needed 
(laboratory evaluation of NO levels). It is well known that 
NO rapidly degrades to nitrite and nitrate (NO2
- and NO3
-) 
in aqueous solution. Therefore, the nitrate and nitrite lev-
els were estimated, to provide an index of NO production. 
Concentration of NO and its metabolites (NO2
- and NO3) 
was measured by spectrometric method in homogenized 
polyp and control specimens. Laboratory analyses were per-
formed in the Scientific Biochemistry Laboratory of Nicolae 
Testemitanu SUMPh.
All statistical analyses were performed using Statistical 
Package for Social Sciences (IBM SPSS Statistics for 
Windows, version 22.0). The Kolmogorov-Smirnov test 
was used to test the normality of data distribution. The data 
were expressed as mean and standard deviations. The chi-
square test was used to compare categorical variables be-
tween groups. The independent sample T-test and Mann 
Whitney-U test were used to compare continuous variables 
between the two groups. Spearman’s rank correlation analy-
ses were used to examine the association between variables. 
Correlations were considered negligible if rs < 0.3, low if 
0.3 < rs < 0.5, moderate if 0.5 < rs < 0.7, high if 0.7 < rs < 0.9, 
and very high if 0.9 < rs < 1.0. Differences were considered 
statistically significant at p value of less than 0.05.
Results
The group 1 (case) was composed of 43 patients with 
nasal polyposis: 26 men and 17 women, with a mean age 
of 48.09±13.56 years (range, 22 to 76 years). The group 2 
(control) was composed of 43 patients with septal devia-
tions and middle concha hypertrophies: 30 men and 13 
women, with a mean age of 33.67±11.44 years (range, 19 to 
65 years). Characteristics of the study populations are given 
in tab. 1. There were no statistically significant differences 
between the two groups regarding gender, residence, use of 
nasal decongestants and VAS score for nasal obstruction (p 
> 0.05), except in terms of distribution of the age. In addi-
tion, patients with NP had a greater VAS score for olfactory 
disorders and SNOT-22 score (p < 0.05), (tab. 1).
Comparison of NO and NO2
-+NO3
- concentrations
There were found significant differences between mean 
NO2
-+NO3
- and NO concentrations in polyp tissues and 
control specimens. Compared to group 2 (control), group 
1 (case) had significantly lower NO2
-+NO3
- concentration 
in tissue specimens (U=123.5, p < 0.001) (tab. 2, Fig. 1B). 
The mean levels of NO were significantly lower in NP tis-
sues than in control specimens (U=173.5, p < 0.001) (tab. 
2, fig. 1A).
Correlation analysis between NO levels and some clinical 
features in study groups
The statistical analysis, performed using Spearman's co-
efficient, showed significant correlations between NO level 
and VAS for nasal obstruction, VAS for olfactory disorder 
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and Lund-Kennedy endoscopic score in case group (tab. 3). 
However, no significant correlations were observed between 
NO level and nasal obstruction, and olfactory disorder in 
control group (p > 0.05 for all) (tab. 3). Furthermore, cor-
relations were found negligible.
While analysing the correlation between the VAS for na-
sal obstruction and NO levels in case group, it was observed 
a low, negative correlation (rs = -0.379, p < 0.05) (tab. 3). 
From the scatterplot (fig. 2A), which relates the VAS for na-
sal obstruction to the NO levels, it may be concluded that 
the increase of nasal obstruction corresponds to the de-
Table 1 






Age (years), Mean±SD 48.09±13.56 33.67±11.44 < 0.001a
Gender (male/female), N 26/17 30/13 0.249b
Residence (urban/rural), N 17/26 18/25 1.0b
Nasal decongestants (naphazoline/ xylometazoline/ oxymetazo-
line/ combined/ several types), N
9/18/2/0/14 5/15/2/1/20 0.482b
VAS score for nasal obstruction, Mean±SD 8.28±1.054 7.81±0.982 0.051a
VAS score for olfactory dysfunctions, Mean±SD 8.35±1.744 1.47±2.25 < 0.001a
Lund-Kennedy endoscopic score, Mean±SD 9.28±2.529 -
SNOT-22 score, Mean±SD 61.79±15.875 50.30±15.26 0.001c
Note: SD, Standard deviation; N, number; VAS, Visual Analog Scale; SNOT-22, SinoNasal Outcome Test-22; – Mann-Whitney-U test; b – Chi-square 
test; c – Independent sample T-test.
Table 2
Comparison of nO and nO2
-+nO3
- concentrations in tissue specimens taken from patients
Characteristics Value p
Group 1 (case) (N1=43) Group 2 (control) (N2=43)
NO2
-+NO3
- (µM/g.prot.) Mean ±SD 1.15±0.54 2.89±1.02 < 0.001a
NO (µM/g.prot.), Mean±SD 0.79±0.49 1.99±0.85 < 0.001a
Note: SD, Standard deviation; a – Mann-Whitney-U test. 
Fig. 1.  Comparison of nO (A) and nO2
-+nO3
- (B) levels in nasal tissues among patients
crease of NO values. A more severe nasal obstructive symp-
toms corresponded to the lower levels of NO. A moderate, 
negative correlation was found between VAS for olfactory 
dysfunctions and NO levels (rs = -0.531, p < 0.001) (tab. 3). 
From the scatterplot (fig. 2 B) it may be concluded that pa-
tients reporting the worst olfactory status were associated 
with the lowest mean of NO. A Spearman’s correlation run 
to determine the relationship between Lund-Kennedy en-
doscopic score and NO levels showed a high, negative corre-
lation between endoscopic score and NO levels (rs = -0.758, 
p < 0.05), (tab. 3 and fig. 2C).
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Discussion
The main findings of this study are summarized as fol-
lows: (1) NO and NO2
-+NO3
- levels in tissues of patients with 
NPs were lower than in patients without NP; (2) Patients 
who had lower NO levels reported a more increased VAS 
score for nasal obstruction and olfactory dysfunction, and a 
more increased endoscopic score. 
NO is a reactive molecule with physiological and patho-
logical effects, mediated by its metabolites rather than the 
NO molecule itself, being involved in a variety of vital pro-
cesses, such as antimicrobial/antiviral activity, blood flow 
regulation, cell metabolism, neurotransmission, immunity, 
inflammation control, platelet function, etc. [16]. NO pro-
duction is catalysed by nitric oxide synthase (NOS). Once 
synthesized, NO acts as an intracellular or extracellular 
messenger. There are known three isoforms of NOS: NOS-1 
(nNOS) and NOS-3 (eNOS) are constitutive isoforms, found 
in neurons and endothelial cells, and NOS-2 (iNOS) is in-
Table 3
Correlations between variables using Spearman’s coefficient






Case group (patients with NP)
NO, µM/g.prot. Spearman’s correlation -0.379* -0.531** -0.758*
P value 0.012 < 0.001 < 0.001
Control group (patients without NP)
NO, µM/g.prot. Spearman’s correlation -0.084 -0.038
P value 0.59 0.80
Note: * - Correlation is significant at the 0.05 level; ** - Correlation is significant at the 0.01 level.
Fig. 2.  Correlation between nO levels and some clinical findings: VAS for nasal obstruction (A),  
VAS for olfactory dysfunctions (B), and Lund-Kennedy endoscopic score (C)
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ducible isoform, found in activated cells during infection or 
inflammation [20, 21]. A number of studies have found that 
exhaled NO is mainly produced in the upper airways [20, 
25], where NO is generated by the paranasal sinus epithe-
lium and then diffuses into the nasal cavities. Therefore, the 
paranasal sinuses appear to be the primary source of NO in 
the respiratory system [21, 27-29].
In this study, there were estimated the NO and NO2
-
+NO3
- levels in tissue specimens, finding the lowest NO and 
NO2
-+NO3
- levels in patients with NP. These results are in 
line with some previous results. Frendo et al. [30] reported 
that nasal NO was significantly lower in patients with NP 
compared with controls. Torretta et al. [31] also showed that 
median nasal NO levels were lower in NP than in controls. 
Arnal et al. [29] demonstrated that NO concentration in na-
sal nonallergic polyposis was significantly decreased com-
pared with both controls and polyposis with allergy. These 
findings contrast with previous results reported by Karlida 
et al. [23], showing an increased tissue NO levels in patients 
with NP. They suggested that inflammatory cells cause more 
excessive free oxygen radicals (FORs), including NO, and 
that natural antioxidants are inadequate for detoxification of 
these FORs. Therefore, undetoxified FORs may cause tissue 
damage and NP [23]. 
The NO2
-+NO3
- concentrations are hardly distinguisha-
ble from those of Bugdayci et al. [32], who demonstrated the 
change in NO2
-/NO3
- levels of nasal polyp patients, report-
ing a higher level of NO2
- and NO3
- than in normal tissue 
(p<0.05). They mentioned that further studies are required 
concerning the significance of changes in lipid peroxidation 
and nitrite levels in pathogenesis of NP [32].
Sadek et al. [25] studying histological and genetical ex-
pression of iNOS to evaluate the role of NO in the patho-
genesis of allergic and non-allergic NP detected that the 
expression of iNOS in both epithelial and stromal layers was 
greater in NP than in control tissues. The allergic NP group 
showed more iNOS expression than those of non-allergic 
NP group. Similarly, Kang et al. [33], studying the expres-
sion of iNOS, and the production of peroxynitrite repre-
sented by the formation of 3-nitrotyrosine (3-NT) by im-
munohistochemistry in nasal polyps, demonstrated that the 
stromal cells of the nasal polyp had higher labeling intensity 
for both iNOS and 3-NT.
Although our results regarding NO levels differ from 
those of Karlidag et al. [23], and NO2
-+NO3
- levels differ 
considerably from those of Bugdayci et al. [32], the differ-
ence could nevertheless be explained. Furthermore, sev-
eral studies, for instance [20, 25, 33], performed on iNOS 
and the levels of NO, showed more iNOS expression and 
upregulation in NP despite lower nasal NO levels than in 
controls. These are possibly related to mechanical blockage 
of the ostiomeatal complex by nasal polyp tissue and failure 
of NO generated constitutively and inducible in the sinuses 
to reach the nasal airway and to diffuse into nasal tissue. 
Colantonio et al. [34] supported that the rise of NO after 
medical and surgical treatment is due to decrease of ob-
struction of sinus ostium. Colantonio et al. propose the fol-
lowing scenario. NO levels, being the result of inducible plus 
constitutive production, in uncomplicated allergic rhinitis 
with patent sinus ostia tend to be elevated, but when inflam-
mation is sufficient to obstruct sinus ostium (as observed in 
NP), NO levels fall.
Patient-reported subjective measures of symptoms, such 
as VAS for nasal obstruction and for olfactory dysfunctions, 
and objective measure such as Lund-Kennedy score were 
assessed in order to correlate the findings with the levels of 
NO. There were found negative correlations that are consist-
ent with previous results [28, 31, 35, 36].
Delclaux et al. [36] conducted a study in which statis-
tical relationships were demonstrated between nasal NO 
and severity scores (clinical: p=-0.31, p=0.015; endoscopic: 
p=-0.57, p<0.0001; CT: p=-0.46, p=0.0005). Torretta et al. 
[32] found that Lund-Mackay scores (CT scores) inversely 
correlated with median NO levels (r=-0.31; p=0.04). Jeong 
et al. [28] observed a significant inverse relationship be-
tween NO levels and sinus CT scores, severity of nasal ob-
struction, and purulent rhinorrhea in chronic rhinosinusi-
tis with polyps. No publications were identified that assess 
the correlation between NO concentrations and endoscopy 
Lund-Kennedy score. However, Nass et al. have found that 
the correlation between CT and nasal endoscopic findings 
in chronic rhinosinusitis diagnosis constitutes 90% [37].
Landis et al. [38] summarized in their review that both 
nasal NO and olfactory function are worth testing routinely 
in any rhinology workup. Regrettably, no evidence for NO 
levels in NP and loss of smell was found. Elsherif et al. [39] 
found that olfactory function and NO concentration cor-
relate in chronic rhinosinusitis patients but not in healthy 
subjects, suggesting that both parameters do not directly 
influence each other. The inflammatory process present in 
chronic rhinosinusitis presumably affects olfaction and NO 
levels. Nasal NO produced by the paranasal sinuses seems 
not to directly influence olfactory function [39].
Our results related to NO levels in NP tissue and rela-
tionship between NO levels and clinical outcomes are in 
agreement with those obtained in earlier studies despite 
some limitations regarding the methodology of assessing 
the NO concentrations and endotypes of recruited patients. 
Conclusions
In conclusion, our results corroborate the previous find-
ings in the literature regarding significantly lower NO lev-
els in NP compared to controls and negative correlation 
between NO levels and nasal obstruction, olfactory distur-
bances, and endoscopic appearance in patients with NP.
This study provides additional insight into complicated 
biological pathways of NO involvement in the pathogenesis 
of NP. Taken together, these results would seem to suggest 
the idea that the levels of NO, generated mainly in paranasal 
sinuses in normal state and pathological one, depend on the 
patency of sinus ostium and the state of osteomeatal com-
plex. NP environment is characterized by abnormalities in 
NO metabolism. Further studies, which take into account 
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the role of NO in different chronic rhinosinusitis endotypes, 
are needed to be undertaken in order to allow an earlier and 
more accurate diagnosis, noninvasive follow-up monitor-
ing, and development of new therapeutic approaches that 
will prevent the harmful direct and indirect effects mediated 
by NO.
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